Jun 21, 2024, 07:47
Blood Cancers Today – Is reduced-duration venetoclax in AML effective?
Blood Cancers Today shared a post on X:
“Is reduced-duration venetoclax in AML effective?
A study presented at EHA2024 by Christophe Willekens, MD, of Gustave Roussy, compares reduced venetoclax exposure of seven days with standard continual venetoclax exposure.”
Read further.
Source: Blood Cancers Today/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 08:59
Nov 13, 2024, 08:39